Faricimab vs Ranibizumab for Neovascular Age-Related Macular Degeneration

In a 2020 phase 2 randomized clinical trial involving patients with neovascular age-related macular degeneration, the mean change in best-corrected visual acuity was no different in patients given intravitreal faricimab (an anti–angiopoietin-2 and anti–vascular endothelial growth factor A monoclonal antibody) every 12 or 16 weeks vs ranibizumab every 4 weeks. This video provides a detailed summary of the trial background, methods, and findings. Faricimab is under evaluation in phase 3 clinical trials for its efficacy and safety in a broader population of patients with neovascular age-related macular degeneration. Click the Related Article link for the full clinical report.